On Tuesday, Denali Therapeutics Inc (NASDAQ: DNLI) was -0.30% drop from the session before settling in for the closing price of $23.29. A 52-week range for DNLI has been $14.56 – $33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 264.19% over the past five years. When this article was written, the company’s average yearly earnings per share was at -163.35%. With a float of $124.63 million, this company’s outstanding shares have now reached $143.84 million.
Let’s look at the performance matrix of the company that is accounted for 445 employees. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Denali Therapeutics Inc stocks. The insider ownership of Denali Therapeutics Inc is 13.40%, while institutional ownership is 88.48%. The most recent insider transaction that took place on Nov 11 ’24, was worth 1,932,665. In this transaction Director of this company sold 59,441 shares at a rate of $32.51, taking the stock ownership to the 9,220 shares. Before that another transaction happened on Nov 07 ’24, when Company’s COFO and Secretary sold 15,558 for $29.91, making the entire transaction worth $465,286. This insider now owns 178,066 shares in total.
Denali Therapeutics Inc (DNLI) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -163.35% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
You can see what Denali Therapeutics Inc (DNLI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -2.91 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc (NASDAQ: DNLI) saw its 5-day average volume 0.9 million, a negative change from its year-to-date volume of 1.05 million. As of the previous 9 days, the stock’s Stochastic %D was 15.41%. Additionally, its Average True Range was 1.12.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 25.61%, which indicates a significant increase from 17.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.89% in the past 14 days, which was lower than the 52.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.17, while its 200-day Moving Average is $23.07. Nevertheless, the first resistance level for the watch stands at $23.48 in the near term. At $23.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $24.10. If the price goes on to break the first support level at $22.86, it is likely to go to the next support level at $22.51. Assuming the price breaks the second support level, the third support level stands at $22.24.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are 143,922K outstanding shares of the company, which has a market capitalization of 3.34 billion. As of now, sales total 330,530 K while income totals -145,220 K. Its latest quarter income was 0 K while its last quarter net income were -107,190 K.
